AML MATTERS

Pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team face challenges in managing acute myeloid leukemia (AML), which is associated with significant morbidity and mortality rates that affect many patients in the United States.

ASCP is a long-standing, proud partner in collaborations designed to meet the needs of multidisciplinary care teams on the optimal testing, diagnosis, evaluation of risk, and personalized treatment of AML.

Online Education Opportunities

To promote continued learning and growth for pathologists and laboratory professionals, ASCP has developed a set of online CheckPath-based cases relating to Acute Myeloid Leukemia (AML), as part of the AML MATTERS program. These CME/CMLE-accredited cases provide a way for laboratory team members to enhance their understanding of the diagnosis and management of AML.

These educational activities consist of virtual slide/digital image-based cases in which participants will be challenged to appropriately diagnose cases of AML.

Upon answering questions for each case, participants will review a full diagnostic interpretation that addresses common mutations in patients with AML, including NPM1 and FLT3-ITD mutations.

These activities are supported by independent educational grants from Astellas Pharma Global Development, Inc. and Bristol-Myers Squibb Company.